Anticancer activities of a benzimidazole compound through sirtuin inhibition in colorectal cancer. (1st August 2018)

• Record Type: Journal Article
• Authors: Tan, Yi Jer; Lee, Yeuan Ting; Yeong, Keng Yoon; Petersen, Sven H; Kono, Koji; Tan, Soo Choon; Oon, Chern Ein
• Is Part Of: Future medicinal chemistry. Volume 10:Number 17(2018)
• Page Start: 2039
• Page End: 2057
• Publication Date: 2018-08-01
• Subjects: BZD9L1 -- colorectal cancer -- sirtuin -- targeted therapy; Pharmaceutical chemistry -- Periodicals; 615.19005
• DOI: 10.4155/fmc-2018-0052
• Languages: English
• ISSNs: 1756-8919

Abstract

Aim: This study aims to investigate the mode of action of a novel sirtuin inhibitor (BZD9L1) and its associated molecular pathways in colorectal cancer (CRC) cells.Materials & methods: BZD9L1 was tested against metastatic CRC cell lines to evaluate cytotoxicity, cell cycle and apoptosis, senescence, apoptosis related genes and protein expressions, as well as effect against major cancer signaling pathways.Results & conclusion: BZD9L1 reduced the viability, cell migration and colony forming ability of both HCT 116 and HT-29 metastatic CRC cell lines through apoptosis. BZD9L1 regulated major cancer pathways differently in CRC with different mutation profiles. BZD9L1 exhibited anticancer activities as a cytotoxic drug in CRC and as a promising therapeutic strategy in CRC treatment. Graphical abstract: